Infection control in cystic fibrosis
- PMID: 14726455
- PMCID: PMC321464
- DOI: 10.1128/CMR.17.1.57-71.2004
Infection control in cystic fibrosis
Abstract
Over the past 20 years there has been a greater interest in infection control in cystic fibrosis (CF) as patient-to-patient transmission of pathogens has been increasingly demonstrated in this unique patient population. The CF Foundation sponsored a consensus conference to craft recommendations for infection control practices for CF care providers. This review provides a summary of the literature addressing infection control in CF. Burkholderia cepacia complex, Pseudomonas aeruginosa, and Staphylococcus aureus have all been shown to spread between patients with CF. Standard precautions, transmission-based precautions including contact and droplet precautions, appropriate hand hygiene for health care workers, patients, and their families, and care of respiratory tract equipment to prevent the transmission of infectious agents serve as the foundations of infection control and prevent the acquisition of potential pathogens by patients with CF. The respiratory secretions of all CF patients potentially harbor clinically and epidemiologically important microorganisms, even if they have not yet been detected in cultures from the respiratory tract. CF patients should be educated to contain their secretions and maintain a distance of >3 ft from other CF patients to avoid the transmission of potential pathogens, even if culture results are unavailable or negative. To prevent the acquisition of pathogens from respiratory therapy equipment used in health care settings as well as in the home, such equipment should be cleaned and disinfected. It will be critical to measure the dissemination, implementation, and potential impact of these guidelines to monitor changes in practice and reduction in infections.
Similar articles
-
Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission.Am J Infect Control. 2003 May;31(3 Suppl):S1-62. Am J Infect Control. 2003. PMID: 12762292 Review. No abstract available.
-
Current infection control practices used in Australian and New Zealand cystic fibrosis centers.BMC Pulm Med. 2020 Jan 17;20(1):16. doi: 10.1186/s12890-020-1052-y. BMC Pulm Med. 2020. PMID: 31952502 Free PMC article.
-
Infection control in cystic fibrosis: cohorting, cross-contamination, and the respiratory therapist.Respir Care. 2009 May;54(5):641-57. doi: 10.4187/aarc0446. Respir Care. 2009. PMID: 19393108 Review.
-
Improved patient safety through reduced airway infection rates in a paediatric cystic fibrosis programme after a quality improvement effort to enhance infection prevention and control measures.BMJ Qual Saf. 2014 Apr;23 Suppl 1:i73-i80. doi: 10.1136/bmjqs-2013-002315. BMJ Qual Saf. 2014. PMID: 24608553
-
Pathophysiology and management of pulmonary infections in cystic fibrosis.Am J Respir Crit Care Med. 2003 Oct 15;168(8):918-51. doi: 10.1164/rccm.200304-505SO. Am J Respir Crit Care Med. 2003. PMID: 14555458 Review.
Cited by
-
Transcriptional response of Burkholderia cenocepacia J2315 sessile cells to treatments with high doses of hydrogen peroxide and sodium hypochlorite.BMC Genomics. 2010 Feb 5;11:90. doi: 10.1186/1471-2164-11-90. BMC Genomics. 2010. PMID: 20137066 Free PMC article.
-
Factors influencing acquisition of Burkholderia cepacia complex organisms in patients with cystic fibrosis.J Clin Microbiol. 2013 Dec;51(12):3975-80. doi: 10.1128/JCM.01360-13. Epub 2013 Sep 18. J Clin Microbiol. 2013. PMID: 24048536 Free PMC article.
-
Burkholderia cenocepacia ShvR-regulated genes that influence colony morphology, biofilm formation, and virulence.Infect Immun. 2011 Aug;79(8):2984-97. doi: 10.1128/IAI.00170-11. Epub 2011 Jun 20. Infect Immun. 2011. PMID: 21690240 Free PMC article.
-
Paediatric nurses' perception of the child-family dyad's autonomy in managing a chronic disease situation: the experience of an Italian paediatric department.J Prev Med Hyg. 2013 Jun;54(2):124-9. J Prev Med Hyg. 2013. PMID: 24396995 Free PMC article.
-
Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment.Pediatr Radiol. 2005 Aug;35(8):739-57. doi: 10.1007/s00247-005-1445-3. Epub 2005 May 3. Pediatr Radiol. 2005. PMID: 15868140 Review.
References
-
- Abman, S. H., J. W. Ogle, N. Butler-Simon, C. M. Rumack, and F. J. Accurso. 1988. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J. Pediatr. 113:826-830. - PubMed
-
- Abman, S. H., J. W. Ogle, R. J. Harbeck, N. Butler-Simon, K. B. Hammond, and F. J. Accurso. 1991. Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening. J. Pediatr. 119:211-217. - PubMed
-
- Aitken, M. L., W. Burke, G. McDonald, C. Wallis, B. Ramsey, and C. Nolan. 1993. Nontuberculous mycobacterial disease in adult cystic fibrosis patients. Chest 103:1096-1099. - PubMed
-
- American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. 1998. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 102:1211-1216. - PubMed
-
- American Thoracic Society. 1997. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am. J. Respir. Crit. Care Med. 156:S1-S25. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous